OPTISON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Optison, and when can generic versions of Optison launch?
Optison is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.
Summary for OPTISON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 70 |
Clinical Trials: | 20 |
Patent Applications: | 2,999 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for OPTISON |
What excipients (inactive ingredients) are in OPTISON? | OPTISON excipients list |
DailyMed Link: | OPTISON at DailyMed |
Recent Clinical Trials for OPTISON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mayo Clinic | Phase 1 |
Covance | Phase 4 |
Chiltern International Inc. | Phase 4 |
Pharmacology for OPTISON
Drug Class | Contrast Agent for Ultrasound Imaging |
Mechanism of Action | Ultrasound Contrast Activity |
Anatomical Therapeutic Chemical (ATC) Classes for OPTISON
US Patents and Regulatory Information for OPTISON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTISON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPTISON
See the table below for patents covering OPTISON around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 663488 | ⤷ Try a Trial | |
Hong Kong | 1012564 | ⤷ Try a Trial | |
Israel | 99438 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 9305819 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTISON
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1853250 | 37/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230 |
0961612 | CA 2009 00036 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PACLITAXELALBUMIN |
1853250 | 300673 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
1853250 | 238 50005-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: PAKLITAXEL VO FORME NANOCASTIC VIAZANYCH NA ALBUMIN; REGISTRATION NO/DATE: EU/1/07/428/001 - EU/1/07/428/002 20131230 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |